Obinutuzumab plus bendamustine in rituximab-refractory indolent lymphoma

被引：2
|
作者：
Hamlin, Paul A. [1 ,2 ,3 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Basking Ridge Med Oncol Serv, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, Div Hematol Oncol, Dept Med, New York, NY 10065 USA
[3] New York Presbyterian Hosp, Dept Med, Weill Cornell Med Coll, New York, NY 10032 USA
来源：
LANCET ONCOLOGY | 2016年 / 17卷 / 08期
关键词：
D O I：
10.1016/S1470-2045(16)30157-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1023 / 1025
页数：4
相关论文
共 50 条
  • [1] OBINUTUZUMAB PLUS BENDAMUSTINE VERSUS BENDAMUSTINE ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY FOLLICULAR LYMPHOMA: RESULTS FROM THE GADOLIN STUDY
    Trneny, M.
    Bouabdallah, K.
    Dueck, G.
    Gribben, J.
    Lugtenburg, P.
    Press, O.
    Salles, G.
    Sehn, L.
    Berge, C.
    Fingerle-Rowson, G.
    Wassner-Fritsch, E.
    Cheson, B.
    HAEMATOLOGICA, 2016, 101 : 155 - 156
  • [2] Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study
    Cheson, Bruce D.
    Trneny, Marek
    Bouabdallah, Kamal
    Dueck, Gregory
    Gribben, John
    Lugtenburg, Pieternella J.
    Press, Oliver
    Salles, Gilles A.
    Fingerle-Rowson, Gunter
    Mattiello, Federico
    Wassner-Fritsch, Elisabeth
    Sehn, Laurie H.
    BLOOD, 2016, 128 (22)
  • [3] Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study
    Cheson, Bruce D.
    Chua, Neil
    Mayer, Jiri
    Dueck, Greg
    Trneny, Marek
    Bouabdallah, Kamal
    Fowler, Nathan
    Delwail, Vincent
    Press, Oliver
    Salles, Gilles
    Gribben, John G.
    Lennard, Anne
    Lugtenburg, Pieternella J.
    Fingerle-Rowson, Gunter
    Mattiello, Federico
    Knapp, Andrea
    Sehn, Laurie H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (22) : 2259 - +
  • [4] GADOLIN: PRIMARY RESULTS FROM A PHASE III STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE COMPARED WITH BENDAMUSTINE ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
    Sehn, L.
    Chua, N.
    Mayer, J.
    Dueck, G.
    Trneny, M.
    Bouabdallah, K.
    Fowler, N.
    Delwail, V.
    Press, O.
    Salles, G.
    Gribben, J.
    Lennard, A.
    Lugtenburg, P.
    Franklin, N.
    Wassner-Fritsch, E.
    Fingerle-Rowson, G.
    Cheson, B.
    HAEMATOLOGICA, 2015, 100 : 273 - 273
  • [5] GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma
    Sehn, Laurie Helen
    Chua, Neil Sun
    Mayer, Jiri
    Dueck, Gregory Scott
    Trneny, Marek
    Bouabdallah, Kamal
    Fowler, Nathan Hale
    Delwail, Vincent
    Press, Oliver W.
    Salles, Gilles A.
    Gribben, John G.
    Lennard, Anne
    Lugtenburg, Pieternella J.
    Franklin, Natalie
    Fritsch, Elisabeth Wassner
    Fingerle-Rowson, Guenter
    Cheson, Bruce D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)
  • [6] Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study
    Sehn, Laurie H.
    Trneny, Marek
    Bouabdallah, Kamal
    Dueck, Gregory
    Gribben, John G.
    Lugtenburg, P. J.
    Salles, Gilles A.
    Knapp, Andrea
    Nielsen, Tina G.
    Liu, Wenxin
    Cheson, Bruce D.
    BLOOD, 2019, 134
  • [7] GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
    Sehn, Laurie Helen
    Chua, Neil Sun
    Mayer, Jiri
    Dueck, Gregory Scott
    Trnen, Marek
    Bouabdallah, Kamal
    Fowler, Nathan Hale
    Delwail, Vincent
    Press, Oliver W.
    Salles, Gilles A.
    Gribben, John G.
    Lennard, Anne
    Lugtenburg, Pieternella J.
    Franklin, Natalie
    Fritsch, Elisabeth Wassner
    Fingerle-Rowson, Guenter
    Cheson, Bruce D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma
    Sohita Dhillon
    Targeted Oncology, 2017, 12 : 255 - 262
  • [9] Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma
    Dhillon, Sohita
    TARGETED ONCOLOGY, 2017, 12 (02) : 255 - 262
  • [10] Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
    Sehn, Laurie H.
    Chua, Neil
    Mayer, Jiri
    Dueck, Gregg
    Trneny, Marek
    Bouabdallah, Kamal
    Fowler, Nathan
    Delwail, Vincent
    Press, Oliver
    Salles, Gilles
    Gribben, John
    Lennard, Anne
    Lugtenburg, Pieternella J.
    Dimier, Natalie
    Wassner-Fritsch, Elisabeth
    Fingerle-Rowson, Guenter
    Cheson, Bruce D.
    LANCET ONCOLOGY, 2016, 17 (08): : 1081 - 1093
12345